Prostate-Specific Antigen and Detecting Early Prostate Cancer: The Importance of Race and Patient Age

  • J. E. Oesterling


Although discovered more than 20 years ago, prostate-specific antigen (PSA) did not receive clinical attention until 1986. Since then, however, it has been the center of intense investigation at both the basic science and clinical levels. As a result, much has been learned about this glycoprotein, and today it must be considered the most useful tumor marker available for the diagnosis and management of prostate cancer (Oesterling 1991). It is superior not only to prostatic acid phosphatase but also to digital rectal examination (DRE).


Prostate Cancer Prostate Specific Antigen Prostate Gland Prostate Volume Serum Prostate Specific Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147:817–821PubMedGoogle Scholar
  2. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479PubMedGoogle Scholar
  3. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH (1992) Screening for prostatic carcinoma with prostate-specific antigen. J Urol 147:841–845PubMedGoogle Scholar
  4. Brendler CB, Carmichael M, Walsh PC, Epstein JI (1993) Radical prostatectomy (RP) for nonpalpable prostate cancer diagnosed by needle biopsy: pathologic and clinical findings. J Urol 149:378AGoogle Scholar
  5. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220PubMedCrossRefGoogle Scholar
  6. Catalona WJ, Bigg SW (1990) Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143:538–543PubMedGoogle Scholar
  7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Copien DE, Yuan JJJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161PubMedCrossRefGoogle Scholar
  8. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 270:948–954PubMedCrossRefGoogle Scholar
  9. Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M (1993) Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71:445–450PubMedCrossRefGoogle Scholar
  10. Cooner WH (1993) Early diagnosis of prostate cancer. In: Campbell’s urology, 6th edn. Saunders, Philadelphia, Update 4:1–10Google Scholar
  11. Crawford ED (1993) Report on the 1992 prostate cancer awareness week. J Urol 149:55AGoogle Scholar
  12. Dalkin BL, Ahmann FR, Kopp JB (1993a) Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837–1839PubMedGoogle Scholar
  13. Dalkin BL, Ahmann F, Southwick P, Bottaccini MR (1993b) Derivation of normal prostate specific antigen (PSA) level by age. J Urol 149:413AGoogle Scholar
  14. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:2650–2658PubMedCrossRefGoogle Scholar
  15. Gerber GS, Thompson IM, Thisted R, Chodak GW (1993) Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269:61–64PubMedCrossRefGoogle Scholar
  16. Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM (1968) The palpable nodule of prostate cancer: results 15 years after radical excision. JAMA 203:403–406PubMedCrossRefGoogle Scholar
  17. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA (1989) Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 141:1091–1094PubMedGoogle Scholar
  18. Klee GG, Dodge LA, Zincke H, Oesterling JE (1994) Measurement of serum prostate specific antigen concentration using IMx prostate specific antigen assay. J Urol 151:94–98PubMedGoogle Scholar
  19. Lilja H, Christensson A, Dahlen V, Matikainen MT, Nilsson O, Pettersson K, Lovgen T (1991) Prostate-specific antigen in human serum occurs predominately in complex with alpha-1-antichymotrypsin. Clin Chem 37:1618–1625PubMedGoogle Scholar
  20. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE (1993) An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 269:2633–2636PubMedCrossRefGoogle Scholar
  21. Oesterling JE (1991) Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923PubMedGoogle Scholar
  22. Oesterling JE, Bilhartz DL, Tindall DJ (1991) Clinically useful serum markers for adenocarcinoma of the prostate. II. Prostate-specific antigen. Am Urol Assoc Update Ser 10:137–144Google Scholar
  23. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993a) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864PubMedCrossRefGoogle Scholar
  24. Oesterling JE, Suman VJ, Bostwick DG, Zincke H (1993b) PSA-detected (clinical stage Tlc or Bo) prostate cancer: pathologically significant tumors. Urol Clin North Am 20:687–693PubMedGoogle Scholar
  25. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, Jacobsen SJ, Lieber MM (1995) Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged Caucasians. Br J Urol 75:347–353PubMedCrossRefGoogle Scholar
  26. Scaletscky R, Koch MO, Eckstein CW, Smith JA Jr (1993) Pathologic findings in prostate cancer detected because of PSA elevation. J Urol 149:303AGoogle Scholar
  27. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz M, Pavone-Macaluso M (1992) The TNM classification of prostate cancer. Prostate [Suppl] 4:129–138CrossRefGoogle Scholar
  28. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226PubMedGoogle Scholar
  29. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE (1993) Clinical stage Bo or Tlc prostate cancer: nonpalpable prostate cancer identified by an elevated serum prostate-specific antigen concentration. Urology 41:3–8PubMedCrossRefGoogle Scholar
  30. Thompson IM, Rounder JB, Teague JL, Peek M, Spence CR (1987) Impact of routine screening for adenocarcinoma of the prostate on stage distribution. J Urol 137:424–426PubMedGoogle Scholar
  31. Vessella RL, Noteboom J, Lange PH (1992) Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 38:2044–2054PubMedGoogle Scholar
  32. Whitmore WF Jr (1993) Management of clinically localized prostate cancer: an unresolved problem. JAMA 269:2676–2677PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • J. E. Oesterling

There are no affiliations available

Personalised recommendations